COMMUNIQUÉS West-GlobeNewswire
-
Heartflow to Participate in the Wells Fargo 21st Annual Healthcare Conference
27/08/2026 -
Outlook Therapeutics Appoints Kevin Lundquist as Chief Financial Officer as It Prepares for U.S. Commercial Launch of LYTENAVA™
27/08/2026 -
Resmed Announces Participation in the 24th Annual Morgan Stanley Global Healthcare Conference
27/08/2026 -
Vaxcyte to Participate in Upcoming Investor Conferences
27/08/2026 -
La Croix-Rouge canadienne recueille des dons pour venir en aide aux personnes touchées par des inondations éclair au Népal
27/08/2026 -
Canadian Red Cross launches appeal to support people impacted by the devastating flash floods in Nepal
27/08/2026 -
Pfizer and BioNTech Receive U.S. FDA Approval for XFG-adapted COVID-19 Vaccine
27/08/2026 -
LeMaitre to Participate at Upcoming Investor Conferences in September
27/08/2026 -
Kane Biotech Announces Second Quarter 2026 Financial Results
27/08/2026 -
Oxford Treatment Center’s Medical Director, Dr. Lucas Trautman, Named a 2026 Health Care Hero by Memphis Business Journal
28/08/2026 -
Jelly Force Male Enhancement Gummies Label Guide: 82 mg Proprietary Blend, Supplement Facts Panel, and 60-Day Guarantee Terms for 2026
28/08/2026 -
University of St. Augustine for Health Sciences Strengthens Community Ties and Champions Hands-on Learning at the 9th Annual U.S. Open Adaptive Surfing Championships
27/08/2026 -
Jersey College York Campus Marks First Graduation and a New Generation of Nurses in Pennsylvania
27/08/2026 -
FDA Issues Emergency Use Authorization for Generic Drug to Prevent New World Screwworm in Cattle
27/08/2026 -
Affordable ACA Alternatives: Common Healthcare Sharing Questions Answered for 2026
27/08/2026 -
Stryker to participate in the 2026 Wells Fargo Healthcare Conference
27/08/2026 -
JATT III Acquisition Corp Announces Closing of $69,000,000 Initial Public Offering
27/08/2026 -
Priovant Announces FDA Approval of LISRAYA™ (brepocitinib) for Adults with Dermatomyositis; Now Available in the U.S.
27/08/2026 -
Roivant Announces FDA Approval of LISRAYA™ (brepocitinib) for Adults with Dermatomyositis; Now Available in the U.S.
27/08/2026
Pages